A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors

Trial Profile

A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tesetaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Mar 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Accrual at the initial dosing level has been completed, according to a Genta media release.
    • 26 Apr 2011 Status changed from not yet recruiting to recruiting, based on a Genta media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top